The Clinical Significance of Circulating Tumour Cells in Breast Cancer and Colorectal Cancer Patients
Background: Circulating tumour cells (CTC) in the blood of cancer patients indicate disease progression. Their presence reflects a relapse or metastasising process since CTC survive only a short time in the circulation. Materials and Methods: Test systems developed by AdnaGen have been used for the...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2007-05, Vol.27 (3A), p.1337-1341 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1341 |
|---|---|
| container_issue | 3A |
| container_start_page | 1337 |
| container_title | Anticancer research |
| container_volume | 27 |
| creator | HAUCH, Siegfried ZIMMERMANN, Silke LANKIEWICZ, Silke ZIEGLSCHMID, Veit BOCHER, Oliver HANS ALBERT, Winfried |
| description | Background: Circulating tumour cells (CTC) in the blood of cancer patients indicate disease progression. Their presence reflects
a relapse or metastasising process since CTC survive only a short time in the circulation. Materials and Methods: Test systems
developed by AdnaGen have been used for the sensitive and specific analysis of CTC. Results: Case reports of 2 breast cancer
patients demonstrate the successful detection of CTC for therapy monitoring purposes. The disappearance of CTC reflects therapy
success. The patient that responded towards therapy was characterized by the disappearance of CTC from the first therapeutic
unit (TU) onwards. In contrast, CTC remained detectable in the other patient during the whole therapy pointing to only limited
therapeutic efficacy and a progressive disease. Furthermore, systematic changes in the expression profile of CTC in colorectal
patients at different stages of disease could be observed. Whereas EGFR was expressed in 90% of the patients with CTC during
primary disease the expression level decreased to 15% in CTC of metastatic patients. On the other hand the expression of CEA
was low in CTC found after primary surgery (15%) and dominant in CTC of metastatic patients (80%). Conclusion: The analysis
of CTC is a useful tool for therapy monitoring of breast cancer and colorectal cancer patients in the adjuvant and palliative
situation. The molecular profiling of CTC may be used to identify therapeutic targets such as HER2 or EGFR for personalised
treatment that is likely to have an important impact on the therapeutic efficacy of drugs like Herceptin® or Erbitux® |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70667953</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70667953</sourcerecordid><originalsourceid>FETCH-LOGICAL-h270t-8151e8791bbd879d5b1dd89b1f7728059d81e3f915c13f898d0bc9f1b7ea513a3</originalsourceid><addsrcrecordid>eNpFkE9LxDAQxYMo7rr6FSQXvRWShmyS4xr8BwsKrueQNsk2kqZr0iJ-eyNW9jTD8Js3894JWGImcMUoQadgiWqKKoYQXYCLnD8QWq8FJ-dggRkVZF3zJbC7zkIZfPStDvDN76N3pY2thYOD0qd2Cnr0cQ93Uz9MCUobQoY-wrtkdR6h_GUT1NFAOYQh2XYsQvP0tazaOOZLcOZ0yPZqrivw_nC_k0_V9uXxWW62VVczNFYcU2x5MdA0phRDG2wMFw12jNUcUWE4tsQJTFtMHBfcoKYVDjfMaoqJJitw-6d7SMPnZPOoep_b8rGOdpiyYiUBJigp4PUMTk1vjTok3-v0rf6DKcDNDOhcknGpGPL5yHGBBCPkeLHz--7LJ6tyr0MoskTpVDNFNgoTwsgPlAx50Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70667953</pqid></control><display><type>article</type><title>The Clinical Significance of Circulating Tumour Cells in Breast Cancer and Colorectal Cancer Patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>HAUCH, Siegfried ; ZIMMERMANN, Silke ; LANKIEWICZ, Silke ; ZIEGLSCHMID, Veit ; BOCHER, Oliver ; HANS ALBERT, Winfried</creator><creatorcontrib>HAUCH, Siegfried ; ZIMMERMANN, Silke ; LANKIEWICZ, Silke ; ZIEGLSCHMID, Veit ; BOCHER, Oliver ; HANS ALBERT, Winfried</creatorcontrib><description>Background: Circulating tumour cells (CTC) in the blood of cancer patients indicate disease progression. Their presence reflects
a relapse or metastasising process since CTC survive only a short time in the circulation. Materials and Methods: Test systems
developed by AdnaGen have been used for the sensitive and specific analysis of CTC. Results: Case reports of 2 breast cancer
patients demonstrate the successful detection of CTC for therapy monitoring purposes. The disappearance of CTC reflects therapy
success. The patient that responded towards therapy was characterized by the disappearance of CTC from the first therapeutic
unit (TU) onwards. In contrast, CTC remained detectable in the other patient during the whole therapy pointing to only limited
therapeutic efficacy and a progressive disease. Furthermore, systematic changes in the expression profile of CTC in colorectal
patients at different stages of disease could be observed. Whereas EGFR was expressed in 90% of the patients with CTC during
primary disease the expression level decreased to 15% in CTC of metastatic patients. On the other hand the expression of CEA
was low in CTC found after primary surgery (15%) and dominant in CTC of metastatic patients (80%). Conclusion: The analysis
of CTC is a useful tool for therapy monitoring of breast cancer and colorectal cancer patients in the adjuvant and palliative
situation. The molecular profiling of CTC may be used to identify therapeutic targets such as HER2 or EGFR for personalised
treatment that is likely to have an important impact on the therapeutic efficacy of drugs like Herceptin® or Erbitux®</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 17593628</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Biological and medical sciences ; Bone Neoplasms - blood ; Bone Neoplasms - secondary ; Breast Neoplasms - blood ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Chemotherapy, Adjuvant ; Colorectal Neoplasms - blood ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - therapy ; Disease Progression ; Gene Expression Profiling ; Gynecology. Andrology. Obstetrics ; Humans ; Lung Neoplasms - blood ; Lung Neoplasms - secondary ; Mammary gland diseases ; Medical sciences ; Neoplasm Staging ; Neoplastic Cells, Circulating - pathology ; Palliative Care ; Radiotherapy, Adjuvant ; RNA, Messenger - biosynthesis ; RNA, Messenger - genetics ; Tumors</subject><ispartof>Anticancer research, 2007-05, Vol.27 (3A), p.1337-1341</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23929,23930,25139</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18909733$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17593628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HAUCH, Siegfried</creatorcontrib><creatorcontrib>ZIMMERMANN, Silke</creatorcontrib><creatorcontrib>LANKIEWICZ, Silke</creatorcontrib><creatorcontrib>ZIEGLSCHMID, Veit</creatorcontrib><creatorcontrib>BOCHER, Oliver</creatorcontrib><creatorcontrib>HANS ALBERT, Winfried</creatorcontrib><title>The Clinical Significance of Circulating Tumour Cells in Breast Cancer and Colorectal Cancer Patients</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: Circulating tumour cells (CTC) in the blood of cancer patients indicate disease progression. Their presence reflects
a relapse or metastasising process since CTC survive only a short time in the circulation. Materials and Methods: Test systems
developed by AdnaGen have been used for the sensitive and specific analysis of CTC. Results: Case reports of 2 breast cancer
patients demonstrate the successful detection of CTC for therapy monitoring purposes. The disappearance of CTC reflects therapy
success. The patient that responded towards therapy was characterized by the disappearance of CTC from the first therapeutic
unit (TU) onwards. In contrast, CTC remained detectable in the other patient during the whole therapy pointing to only limited
therapeutic efficacy and a progressive disease. Furthermore, systematic changes in the expression profile of CTC in colorectal
patients at different stages of disease could be observed. Whereas EGFR was expressed in 90% of the patients with CTC during
primary disease the expression level decreased to 15% in CTC of metastatic patients. On the other hand the expression of CEA
was low in CTC found after primary surgery (15%) and dominant in CTC of metastatic patients (80%). Conclusion: The analysis
of CTC is a useful tool for therapy monitoring of breast cancer and colorectal cancer patients in the adjuvant and palliative
situation. The molecular profiling of CTC may be used to identify therapeutic targets such as HER2 or EGFR for personalised
treatment that is likely to have an important impact on the therapeutic efficacy of drugs like Herceptin® or Erbitux®</description><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - blood</subject><subject>Bone Neoplasms - secondary</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Colorectal Neoplasms - blood</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Disease Progression</subject><subject>Gene Expression Profiling</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - secondary</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Neoplasm Staging</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Palliative Care</subject><subject>Radiotherapy, Adjuvant</subject><subject>RNA, Messenger - biosynthesis</subject><subject>RNA, Messenger - genetics</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE9LxDAQxYMo7rr6FSQXvRWShmyS4xr8BwsKrueQNsk2kqZr0iJ-eyNW9jTD8Js3894JWGImcMUoQadgiWqKKoYQXYCLnD8QWq8FJ-dggRkVZF3zJbC7zkIZfPStDvDN76N3pY2thYOD0qd2Cnr0cQ93Uz9MCUobQoY-wrtkdR6h_GUT1NFAOYQh2XYsQvP0tazaOOZLcOZ0yPZqrivw_nC_k0_V9uXxWW62VVczNFYcU2x5MdA0phRDG2wMFw12jNUcUWE4tsQJTFtMHBfcoKYVDjfMaoqJJitw-6d7SMPnZPOoep_b8rGOdpiyYiUBJigp4PUMTk1vjTok3-v0rf6DKcDNDOhcknGpGPL5yHGBBCPkeLHz--7LJ6tyr0MoskTpVDNFNgoTwsgPlAx50Q</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>HAUCH, Siegfried</creator><creator>ZIMMERMANN, Silke</creator><creator>LANKIEWICZ, Silke</creator><creator>ZIEGLSCHMID, Veit</creator><creator>BOCHER, Oliver</creator><creator>HANS ALBERT, Winfried</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20070501</creationdate><title>The Clinical Significance of Circulating Tumour Cells in Breast Cancer and Colorectal Cancer Patients</title><author>HAUCH, Siegfried ; ZIMMERMANN, Silke ; LANKIEWICZ, Silke ; ZIEGLSCHMID, Veit ; BOCHER, Oliver ; HANS ALBERT, Winfried</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h270t-8151e8791bbd879d5b1dd89b1f7728059d81e3f915c13f898d0bc9f1b7ea513a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - blood</topic><topic>Bone Neoplasms - secondary</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Colorectal Neoplasms - blood</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Disease Progression</topic><topic>Gene Expression Profiling</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - secondary</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Neoplasm Staging</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Palliative Care</topic><topic>Radiotherapy, Adjuvant</topic><topic>RNA, Messenger - biosynthesis</topic><topic>RNA, Messenger - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HAUCH, Siegfried</creatorcontrib><creatorcontrib>ZIMMERMANN, Silke</creatorcontrib><creatorcontrib>LANKIEWICZ, Silke</creatorcontrib><creatorcontrib>ZIEGLSCHMID, Veit</creatorcontrib><creatorcontrib>BOCHER, Oliver</creatorcontrib><creatorcontrib>HANS ALBERT, Winfried</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HAUCH, Siegfried</au><au>ZIMMERMANN, Silke</au><au>LANKIEWICZ, Silke</au><au>ZIEGLSCHMID, Veit</au><au>BOCHER, Oliver</au><au>HANS ALBERT, Winfried</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Clinical Significance of Circulating Tumour Cells in Breast Cancer and Colorectal Cancer Patients</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2007-05-01</date><risdate>2007</risdate><volume>27</volume><issue>3A</issue><spage>1337</spage><epage>1341</epage><pages>1337-1341</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: Circulating tumour cells (CTC) in the blood of cancer patients indicate disease progression. Their presence reflects
a relapse or metastasising process since CTC survive only a short time in the circulation. Materials and Methods: Test systems
developed by AdnaGen have been used for the sensitive and specific analysis of CTC. Results: Case reports of 2 breast cancer
patients demonstrate the successful detection of CTC for therapy monitoring purposes. The disappearance of CTC reflects therapy
success. The patient that responded towards therapy was characterized by the disappearance of CTC from the first therapeutic
unit (TU) onwards. In contrast, CTC remained detectable in the other patient during the whole therapy pointing to only limited
therapeutic efficacy and a progressive disease. Furthermore, systematic changes in the expression profile of CTC in colorectal
patients at different stages of disease could be observed. Whereas EGFR was expressed in 90% of the patients with CTC during
primary disease the expression level decreased to 15% in CTC of metastatic patients. On the other hand the expression of CEA
was low in CTC found after primary surgery (15%) and dominant in CTC of metastatic patients (80%). Conclusion: The analysis
of CTC is a useful tool for therapy monitoring of breast cancer and colorectal cancer patients in the adjuvant and palliative
situation. The molecular profiling of CTC may be used to identify therapeutic targets such as HER2 or EGFR for personalised
treatment that is likely to have an important impact on the therapeutic efficacy of drugs like Herceptin® or Erbitux®</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>17593628</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2007-05, Vol.27 (3A), p.1337-1341 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70667953 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Biological and medical sciences Bone Neoplasms - blood Bone Neoplasms - secondary Breast Neoplasms - blood Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - therapy Chemotherapy, Adjuvant Colorectal Neoplasms - blood Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Disease Progression Gene Expression Profiling Gynecology. Andrology. Obstetrics Humans Lung Neoplasms - blood Lung Neoplasms - secondary Mammary gland diseases Medical sciences Neoplasm Staging Neoplastic Cells, Circulating - pathology Palliative Care Radiotherapy, Adjuvant RNA, Messenger - biosynthesis RNA, Messenger - genetics Tumors |
| title | The Clinical Significance of Circulating Tumour Cells in Breast Cancer and Colorectal Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T16%3A50%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Clinical%20Significance%20of%20Circulating%20Tumour%20Cells%20in%20Breast%20Cancer%20and%20Colorectal%20Cancer%20Patients&rft.jtitle=Anticancer%20research&rft.au=HAUCH,%20Siegfried&rft.date=2007-05-01&rft.volume=27&rft.issue=3A&rft.spage=1337&rft.epage=1341&rft.pages=1337-1341&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70667953%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70667953&rft_id=info:pmid/17593628&rfr_iscdi=true |